Safety and efficacy of fractional CO2 laser treatment to the vestibule: a randomized, double-blind, sham-controlled, prospective 3-site clinical study in women with vestibular pain.
暂无分享,去创建一个
[1] M. Franchi,et al. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis. , 2022, The journal of sexual medicine.
[2] C. Uzan,et al. Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms , 2020, Archives of Gynecology and Obstetrics.
[3] G. Pantaleo,et al. CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial , 2020, Climacteric : the journal of the International Menopause Society.
[4] L. McLean,et al. The Overactive Pelvic Floor (OPF) and Sexual Dysfunction. Part 2: Evaluation and Treatment of Sexual Dysfunction in OPF Patients. , 2020, Sexual medicine reviews.
[5] M. Shariat,et al. The Effect of the CO2 Fractional Laser or Premarin Vaginal Cream on Improving Sexual Function in Menopausal Women: A Randomized Controlled Trial. , 2020, Journal of lasers in medical sciences.
[6] S. Bunyavejchevin,et al. Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial. , 2020, Menopause.
[7] C. Juliato,et al. Efficacy of Fractional CO2 Laser, Promestriene, and Vaginal Lubricant in the Treatment of Urinary Symptoms in Postmenopausal Women: A Randomized Clinical Trial , 2020, Lasers in surgery and medicine.
[8] C. Evans,et al. The Vulvodynia Experience Questionnaire: Qualitative Development of a New Patient-Reported Outcome Measure for Vulvodynia. , 2019, The journal of sexual medicine.
[9] B. Ramaswamy,et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors , 2019, Supportive Care in Cancer.
[10] I. Goldstein. The Sexual Pain Lesson: If at First You Don't Succeed…. , 2019, Sexual Medicine Reviews.
[11] I. Goldstein,et al. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause , 2019, Expert review of endocrinology & metabolism.
[12] L. Costa-Paiva,et al. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. , 2019, Menopause.
[13] L. Hayward,et al. Pelvic Floor Dysfunction And Its Effect On Quality Of Sexual Life. , 2019, Sexual medicine reviews.
[14] I. Goldstein,et al. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices , 2019, Menopause.
[15] A. Stein,et al. The Role of Physical Therapy in Sexual Health in Men and Women: Evaluation and Treatment. , 2019, Sexual medicine reviews.
[16] J. Anger,et al. Female Sexual Dysfunction: A Systematic Review of Outcomes Across Various Treatment Modalities. , 2018, Sexual medicine reviews.
[17] C. Iglesia,et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. , 2019, Menopause.
[18] J. Simon,et al. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data , 2018, Current medical research and opinion.
[19] Andrew K Rabley,et al. Laser Therapy for Genitourinary Syndrome of Menopause , 2018, Current Urology Reports.
[20] I. Goldstein,et al. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study , 2018, Sexual medicine.
[21] R. Vallone,et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study , 2017, Menopause.
[22] C. Fernandes,et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women , 2017, Menopause.
[23] M. Candiani,et al. Sexual Function in Women Suffering From Genitourinary Syndrome of Menopause Treated With Fractionated CO2 Laser. , 2017, Sexual medicine reviews.
[24] M. Karram,et al. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes , 2017, Menopause.
[25] R. Baser,et al. Validation of Clinical Tools for Vaginal and Vulvar Symptom Assessment in Cancer Patients and Survivors. , 2017, The journal of sexual medicine.
[26] S. Salvatore,et al. Fractional CO2 Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. , 2016, The journal of sexual medicine.
[27] S. Salvatore,et al. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study. , 2016, Maturitas.
[28] M. Falagas,et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women , 2016, Climacteric : the journal of the International Menopause Society.
[29] A. Becorpi,et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors , 2016, Archives of Gynecology and Obstetrics.
[30] J. Bornstein,et al. 2015 ISSVD, ISSWSH, and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. , 2016, The journal of sexual medicine.
[31] Candace S. Brown,et al. Vulvodynia: Assessment and Treatment. , 2016, The journal of sexual medicine.
[32] G. Bachmann,et al. Vulvodynia: Definition, Prevalence, Impact, and Pathophysiological Factors. , 2016, The journal of sexual medicine.
[33] N. Panay,et al. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? , 2015, Climacteric : the journal of the International Menopause Society.
[34] S. Palacios,et al. Treatment of the genitourinary syndrome of menopause , 2015, Climacteric : the journal of the International Menopause Society.
[35] C. Labrie,et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone) , 2015, Menopause.
[36] M. Candiani,et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study , 2015, Menopause.
[37] R. Rosen,et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial , 2014, Climacteric : the journal of the International Menopause Society.
[38] I. Goldstein,et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. , 2014, The journal of sexual medicine.
[39] D. Portman,et al. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society , 2014, Menopause.
[40] S. Ferrero,et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study , 2014, Climacteric : the journal of the International Menopause Society.
[41] S. Rydell,et al. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. , 2014, American journal of obstetrics and gynecology.
[42] E. Petersen,et al. Vaginal wet mount. , 2013, The journal of sexual medicine.
[43] L. Burrows,et al. The Treatment of Vestibulodynia with Topical Estradiol and Testosterone , 2013, Sexual medicine.
[44] L. Burrows,et al. The effects of hormonal contraceptives on female sexuality: a review. , 2012, The journal of sexual medicine.
[45] Lizheng Shi,et al. Economic burden and quality of life of vulvodynia in the United States , 2012, Current medical research and opinion.
[46] Ananda Sen,et al. Prevalence and demographic characteristics of vulvodynia in a population-based sample. , 2012, American journal of obstetrics and gynecology.
[47] I. Goldstein,et al. Can oral contraceptives cause vestibulodynia? , 2010, The journal of sexual medicine.
[48] C. Pukall,et al. Pain, psychosocial, sexual, and psychophysical characteristics of women with primary vs. secondary provoked vestibulodynia. , 2009, The journal of sexual medicine.
[49] L. Derogatis,et al. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. , 2008, The journal of sexual medicine.
[50] L. Burrows,et al. Continuing medical education , 2007, Movement disorders : official journal of the Movement Disorder Society.
[51] Teri Stone-Godena. Vulvar pain syndromes: vestibulodynia. , 2006, Journal of midwifery & women's health.
[52] Crista E. Johnson,et al. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. , 2006, The journal of sexual medicine.
[53] D. Eschenbach,et al. Women's sexual pain and its management. , 2005, The journal of sexual medicine.
[54] J. Brisson,et al. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. , 2002, American journal of epidemiology.
[55] Candace S. Brown,et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. , 2000, Journal of sex & marital therapy.
[56] G. Sant,et al. The interstitial cystitis symptom index and problem index. , 1998, Urology.
[57] Ronald Melzack,et al. The short-form McGill pain questionnaire , 1987, Pain.